Nuvalent (NUVL) Total Non-Current Liabilities (2024 - 2026)
Nuvalent (NUVL) reported Total Non-Current Liabilities of $156.8 million for Q1 2026, up 66.07% on a YoY basis from $94.4 million in Q1 2025, and down 4.59% quarter-over-quarter from $164.3 million in Q4 2025.
Nuvalent (NUVL) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Nuvalent has reported Total Non-Current Liabilities for 3 years, with the latest figure at $156.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 66.07% year-over-year to $156.8 million; the trailing twelve-month figure through Mar 2026 stood at $156.8 million (up 66.07% YoY), and the FY2025 full-year result was $164.3 million, up 128.36% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $156.8 million, down from $164.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $164.3 million in Q4 2025, with the low at $51.1 million in Q3 2024.
- Historically, Total Non-Current Liabilities has averaged $110.5 million across 3 years, with a median of $100.6 million in 2025.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities surged 162.79% — and 2026, when it jumped 66.07%.
- Nuvalent's Total Non-Current Liabilities stood at $72.0 million in 2024, then surged by 128.36% to $164.3 million in 2025, then retreated by 4.59% to $156.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $156.8 million (Q1 2026), $164.3 million (Q4 2025), and $134.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 156.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.78 Mn |
| Dec 31, 2025 | 164.33 Mn |
| Sep 30, 2025 | 134.37 Mn |
| Jun 30, 2025 | 100.56 Mn |
| Mar 31, 2025 | 94.40 Mn |
| Dec 31, 2024 | 71.96 Mn |
| Sep 30, 2024 | 51.13 Mn |